Teclistamab
drugOn this page
Also known as BCMAxCD3Jnj 64007957JNJ-64007957Teclistamab cqyvTeclistamab-cqyvTecvayli
Summary
Teclistamab (CHEMBL4594505) is an approved antibody (ATC L01FX24); indicated across 4 conditions including plasma cell myeloma and neoplasm.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: L01FX24
- Indications: 4 conditions
- Clinical trials: 50
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4594505 |
| Name | Teclistamab |
| Type | Antibody |
| Max phase | 4 |
| ATC | L01FX24 |
Also known as: BCMAxCD3, Jnj 64007957, JNJ-64007957, Teclistamab, Teclistamab cqyv, Teclistamab-cqyv, Tecvayli, TECLISTAMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| plasma cell myeloma | 4 | MONDO:0009693 | EFO:0001378 |
| neoplasm | 4 | MONDO:0005070 | MONDO:0004992 |
| hematologic disorder | 1 | MONDO:0005570 | MONDO:0005570 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 50.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 21 |
| PHASE1 | 10 |
| PHASE3 | 7 |
| Not specified | 6 |
| PHASE1/PHASE2 | 4 |
| PHASE4 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06251076 | PHASE4 | RECRUITING | Plan Development for Giving Teclistamab in the Outpatient Setting |
| NCT07030517 | PHASE4 | RECRUITING | A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma |
| NCT05083169 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma |
| NCT05243797 | PHASE3 | RECRUITING | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation |
| NCT05552222 | PHASE3 | RECRUITING | A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma |
| NCT05572515 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma |
| NCT06208150 | PHASE3 | RECRUITING | A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide |
| NCT07258511 | PHASE3 | RECRUITING | A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma |
| NCT07518186 | PHASE3 | NOT_YET_RECRUITING | A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma |
| NCT04068597 | PHASE1/PHASE2 | RECRUITING | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies |
| NCT04557098 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma |
| NCT04586426 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma |
| NCT04696809 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma |
| NCT05469893 | PHASE2 | RECRUITING | Immuno-PRISM (PRecision Intervention Smoldering Myeloma) |
| NCT05572229 | PHASE2 | RECRUITING | Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma |
| NCT05695508 | PHASE2 | RECRUITING | GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 |
| NCT05849610 | PHASE2 | ACTIVE_NOT_RECRUITING | Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma |
| NCT05972135 | PHASE2 | RECRUITING | Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma |
| NCT06100237 | PHASE2 | RECRUITING | Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) |
| NCT06171685 | PHASE2 | RECRUITING | MMRC Horizon One: RRMM (MMRC-099) |
| NCT06353022 | PHASE2 | ACTIVE_NOT_RECRUITING | Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma |
| NCT06505369 | PHASE2 | RECRUITING | Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients |
| NCT06577025 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma |
| NCT06649695 | PHASE2 | RECRUITING | A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis |
| NCT06758375 | PHASE2 | RECRUITING | Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients |
| NCT06880601 | PHASE2 | NOT_YET_RECRUITING | Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma |
| NCT06935162 | PHASE2 | RECRUITING | Teclistamab in Previously Treated AL Amyloidosis |
| NCT06948084 | PHASE2 | NOT_YET_RECRUITING | Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse |
| NCT06993675 | PHASE2 | RECRUITING | Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) |
| NCT07079423 | PHASE2 | RECRUITING | Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis |
| NCT07107529 | PHASE2 | RECRUITING | Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. |
| NCT07110844 | PHASE2 | RECRUITING | Teclistamab-Daratumumab in AL Amyloidosis |
| NCT07463807 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment |
| NCT07605416 | PHASE2 | NOT_YET_RECRUITING | Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial |
| NCT03145181 | PHASE1 | ACTIVE_NOT_RECRUITING | Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma |
| NCT04108195 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma |
| NCT04722146 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma |
| NCT05338775 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma |
| NCT06425991 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma |
| NCT06465316 | PHASE1 | RECRUITING | Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: plasma cell myeloma, neoplasm